Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and of gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and hemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Quote | Sangui Biotech Intl Inc (OTCMKTS:SGBI)
Last: | $0.0015 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0015 |
Close: | $0.0015 |
High: | $0.0015 |
Low: | $0.0015 |
Volume: | 200,000 |
Last Trade Date Time: | 01/17/2024 03:00:00 am |
News | Sangui Biotech Intl Inc (OTCMKTS:SGBI)
WITTEN / ACCESSWIRE / March 06, 2019 / The European Patent Office has granted a patent for Sangui's proposed technology/treatment (SBT 102) for septic shock patients, effective March, 6, 2019*. The patent follows up on animal studies carried out by the ECCPS (Excellence Cluster Cardio-Pulmon...
Message Board Posts | Sangui Biotech Intl Inc (OTCMKTS:SGBI)
Subject | By | Source | When |
---|---|---|---|
Nice day here! | nickeli54 | investorshub | 10/04/2021 2:52:36 PM |
PATENT GRANTED: https://www.accesswire.com/538177/Sangui-BioTech-International-I | daytrader868 | investorshub | 03/06/2019 1:19:13 PM |
When is the fda goiing to start the | Gowvu | investorshub | 02/02/2018 6:25:48 AM |
here's some buying coming through.... | gwat1979 | investorshub | 01/02/2018 8:56:13 PM |
The germans did not catch it, yet ? | paulsbest | investorshub | 11/14/2017 2:10:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Sangui Biotech Intl Inc Company Name:
SGBI Stock Symbol:
OTCMKTS Market:
Sangui Biotech Intl Inc Website:
WITTEN / ACCESSWIRE / March 06, 2019 / The European Patent Office has granted a patent for Sangui's proposed technology/treatment (SBT 102) for septic shock patients, effective March, 6, 2019*. The patent follows up on animal studies carried out by the ECCPS (Excellence Cluster Cardio-Pulmon...